苯达莫司汀在淋巴系统恶性肿瘤中的临床应用进展  

Clinical application progress of bendamustine in lymphocytic malignancy

作　　者：马军[1] 

机构地区：[1]哈尔滨血液病肿瘤研究所,150010

出　　处：《白血病．淋巴瘤》2016年第4期193-198,共6页Journal of Leukemia & Lymphoma

摘　　要：盐酸苯达莫司汀是一种双功能烷化剂，对许多肿瘤有临床活性。作为新出现的氮芥类抗肿瘤药物，苯达莫司汀显著提高了患者的耐受性，且没有降低临床活性。虽然已被广泛应用了40多年，但直到20世纪90年代，才在淋巴系统疾病中得到了系统的研究。苯达莫司汀分子较其他烷化剂分子更稳定，能引起更广泛和更持久的DNA损伤。苯达莫司汀的作用机制尚不明确，但是已成为一个独特的抗肿瘤药物。不像其他的烷化剂，苯达莫司汀主要的作用靶点是切除修复通路，而不是错配修复通路，激活DNA损伤应急反应，诱导凋亡，抑制有丝分裂检查点和诱导有丝分裂障碍。文章就苯达莫司汀治疗慢性淋巴细胞白血病、惰性非霍奇金淋巴瘤、弥漫大B细胞淋巴瘤、套细胞淋巴瘤、外周T细胞淋巴瘤以及霍奇金淋巴瘤中的作用进行综述。Bendamustine hydrochloride is a bifunctional alkylating agent with clinical activity to a number of cancers. Bendamustine, an emerging nitrogen mustards anticancer agent, can improve tolerability without sacrificing clinical activity. Although bendamustine has been used widely for more than 40 years, it was not systematically studied in lymphoproliferative disorders until the 1990s. Bendamustine molecule is more stable than the molecules of other alkylators, and it can cause more extensive and more durable damage to DNA . Unlike other alkylating agents, primary targets of bendamustine are based on excision repair pathways rather than mismatch repair pathways, and it activates DNA damage stress responses, induces apoptosis, inhibits mitotic checkpoints, and induces mitotic catastrophe. This paper will review the role of bendamustine in chronic lymphoblastie leukemia（CLL）, indolent non-Hodgkin＇s lymphoma （NHL）, diffuse large B-cell lymphoma （DLBCL）, mantle cell lymphoma （MCL）, peripheral T-cell lymphoma （PTCL）, and Hodgkin＂ s lymphoma （HL）.

关 键 词：苯达莫司汀 淋巴系统恶性肿瘤 

分 类 号：R733[医药卫生—肿瘤]